Related Experiment Video
Updated: Aug 30, 2026

Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors
Published on: July 16, 2012
HIV/HCV co-infection: the magnitude of the problem
E Balestra1, S Aquaro, C F Perno
1Department of Experimental Medicine and Biochemical Sciences, University of Rome Tor Vergata, Rome, Italy.
Insights
Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) coinfection accelerates liver and immune damage. New research is crucial to define optimal therapeutic strategies for managing coinfection effectively.
Area of Science:
- Virology
- Immunology
- Hepatology
Background:
- Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) share transmission routes, leading to frequent coinfection.
- Increased survival of HIV-infected individuals has heightened the clinical significance of HCV-related pathologies.
- HCV and HIV interactions accelerate both liver disease and immunological damage.
Purpose of the Study:
- To highlight the clinical relevance of HIV/HCV coinfection.
- To emphasize the need for effective therapeutic strategies against both viruses.
- To call for innovative research on HIV/HCV interactions.
Main Methods:
- Review of existing literature on HIV/HCV coinfection.
- Analysis of viral interactions and disease progression.
- Identification of therapeutic challenges and research gaps.
Main Results:
- HIV/HCV coinfection significantly exacerbates liver and immune system damage.
- Current therapeutic strategies for coinfection are not fully defined regarding timing and drug combinations.
- Existing knowledge on viral interactions during coinfection is limited.
Conclusions:
- Effective management of HIV/HCV coinfection requires strategies targeting both viruses.
- Further research is essential to understand viral interplay and optimize treatment.
- Defining optimal drug types, timing, and combinations is critical for coinfection management.
Abstract:
Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) share routes of transmission, therefore their coinfection is relatively common. Nevertheless, the clinical relevance of this event has been minimal until few years ago when, due to the increased survival of HIV-infected individuals (favoured by highly active antiretroviral therapy) morbility and mortality caused by pathologies not strictly related to HIV (such as HCV infection) raised sharply. Despite differences in their general characteristics (including lifecycle, target cells, and type of persistence in the infected host) a remarkable level of interaction exists between HCV and HIV; this makes the progression of both liver disease and immunological damage easier and more rapid. A therapeutic approach to HIV/HCV coinfection thus requires the utilization of drugs and strategies effective against both viruses, yet, timing, drug types, and effective combinations still remain poorly defined. New and innovative studies specifically focused on HIV/HCV coinfection are thus warranted to increase the knowledge about their interaction, and define therapeutic strategies aimed to the best management of the infection by both viruses during coinfection.
Related Concept Videos
Hepatitis
Viral Hepatitis I: Introduction
Retrovirus Life Cycles
Cytomegalovirus Disease
Sexually Transmitted Infections
Immunodeficiency Diseases
There are three main causes of immunodeficiency disorders...
